STOCK TITAN

Mirum Pharmaceuticals - MIRM STOCK NEWS

Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.

Mirum Pharmaceuticals, Inc. (symbol: MIRM) is a biopharmaceutical company headquartered in Foster City, California. Established in 2018, the company focuses on the development and commercialization of innovative therapies aimed at treating debilitating liver diseases. Mirum Pharmaceuticals is dedicated to addressing rare and orphan diseases, making significant strides in this niche sector of the healthcare market.

At the core of Mirum Pharmaceuticals' product pipeline is Maralixibat, an investigational oral drug currently in phase 3 clinical trials. Maralixibat is being studied for its efficacy in treating several severe liver conditions, including Progressive Familial Intrahepatic Cholestasis (PFIC), Alagille Syndrome (ALGS), and Biliary Atresia. This product represents a potential breakthrough in providing therapeutic options for these challenging conditions.

In addition, the company has developed Volixibat, a drug aimed at treating Intrahepatic Cholestasis of Pregnancy (ICP) and Primary Sclerosing Cholangitis (PSC). These ongoing projects highlight Mirum Pharmaceuticals' commitment to advancing the treatment landscape for liver diseases with significant unmet medical needs.

Mirum Pharmaceuticals has achieved notable milestones, such as the approval of Livmarli, an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor. Livmarli is approved for the treatment of cholestatic pruritus in patients with Alagille Syndrome (ALGS), providing much-needed relief for those affected by this condition.

The company stands out for its strategic approach to identifying, acquiring, and developing novel therapies. It has established partnerships and collaborations to bolster its research endeavors and expand its reach in the biopharmaceutical industry. With a robust pipeline and a clear focus on debilitating liver diseases, Mirum Pharmaceuticals continues to make significant progress in its mission to improve patient outcomes and quality of life.

For the latest news and updates about Mirum Pharmaceuticals, including recent achievements, ongoing projects, and financial performance, investors and stakeholders can rely on resources like StockTitan for comprehensive and timely information.

Stay informed about Mirum Pharmaceuticals, Inc. and its groundbreaking work in the biopharmaceutical sector, and keep track of the latest developments and stock performance on StockTitan.

Rhea-AI Summary

On September 10, 2021, Mirum Pharmaceuticals (Nasdaq: MIRM) announced the grant of non-qualified stock option awards for 87,500 shares to ten new employees as part of its 2020 Inducement Plan. The options have an exercise price of $18.21 and will vest over four years. Mirum's lead product, maralixibat, is under FDA priority review for cholestatic pruritus in Alagille syndrome, with a PDUFA date of September 29, 2021. The company is also developing gene therapies for PFIC2 and PFIC3, enhancing its pipeline in liver diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
none
-
Rhea-AI Summary

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced its participation in five investor conferences during September 2021. Key events include the Citi 16th Annual BioPharma Virtual Conference on September 10, and the H.C. Wainwright Global Investor Conference from September 13-14, featuring a company presentation. Additional conferences include the Baird Global Healthcare Conference, the Leerink CyberRX Series 1x1 Event, and the Cantor Global Healthcare Conference. Mirum focuses on innovative therapies for liver diseases, with its lead candidate, maralixibat, under FDA priority review.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
conferences
-
Rhea-AI Summary

Mirum Pharmaceuticals has appointed William C. Fairey to its Board of Directors, bringing nearly 30 years of experience in global commercial strategy, particularly in rare diseases. His appointment coincides with the resignation of Tiba Aynechi, effective August 19, 2021. Fairey’s role will be vital as Mirum prepares for the U.S. launch of its first medication and advances its pipeline of therapies for rare liver diseases. The company’s lead candidate, maralixibat, is under priority review by the FDA, with a decision expected by September 29, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
management
Rhea-AI Summary

Mirum Pharmaceuticals (Nasdaq: MIRM) announced on August 10, 2021, that it granted non-qualified stock option awards for 95,200 shares to eight new employees as an inducement under its 2020 Inducement Plan. The options have an exercise price of $14.05 per share, reflecting the closing price on the grant date, and will vest over four years. Furthermore, the company is advancing its pipeline, including maralixibat, which is under priority review for treating cholestatic pruritus, with a PDUFA date of September 29, 2021. Mirum also acquired options for two gene therapy programs from Vivet Therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
none
-
Rhea-AI Summary

Mirum Pharmaceuticals (Nasdaq: MIRM) announced its financial results for Q2 2021, reporting a net loss of $43.9 million, or $1.45 per share, compared to a loss of $23.3 million in Q2 2020. Licensing revenue rose to $11.0 million, reflected in a collaboration with CANbridge Pharmaceuticals. Total operating expenses surged to $48.4 million, influenced by increased research and development costs. Looking ahead, the FDA has set a PDUFA date of September 29, 2021, for maralixibat, with a commercial opportunity exceeding $500 million. The company is advancing its clinical pipeline with multiple expected data releases in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
-
Rhea-AI Summary

Mirum Pharmaceuticals (Nasdaq: MIRM) will announce its financial results for Q2 2021 on August 5, 2021, at 1:30 p.m. PT/4:30 p.m. ET, followed by a conference call for business updates. The lead product, maralixibat, targets debilitating liver diseases and has a New Drug Application (NDA) under priority review by the FDA, with a PDUFA date of September 29, 2021. Additionally, Mirum is expanding its portfolio through exclusive options for gene therapy programs aimed at treating PFIC3 and PFIC2.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
conferences earnings
Rhea-AI Summary

Mirum Pharmaceuticals has entered into an exclusive licensing agreement with GC Pharma for the development and commercialization of maralixibat in South Korea. Maralixibat is under investigation for treating Alagille syndrome, progressive familial intrahepatic cholestasis, and biliary atresia. Mirum will receive an upfront payment of $5 million along with potential milestone payments and tiered royalties based on net sales. The FDA has accepted a New Drug Application for maralixibat for cholestatic pruritus with a review due by September 29, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.48%
Tags
none
-
Rhea-AI Summary

Mirum Pharmaceuticals (Nasdaq: MIRM) announced that its Board's Compensation Committee granted non-qualified stock options for 146,400 shares to 10 new employees as part of the 2020 Inducement Plan. The exercise price is set at $16.61, Mirum's closing price on July 12, 2021, with a four-year vesting schedule. Mirum is focused on developing therapies for liver diseases, with lead candidate maralixibat under FDA review for cholestatic pruritus in Alagille syndrome and ongoing projects in pediatric PFIC. The company is also expanding its pipeline through gene therapy programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
none
-
Rhea-AI Summary

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) will participate in Piper Sandler’s Virtual EASL Takeaway Day on June 28, 2021, at 2:00 p.m. ET, featuring CEO Chris Peetz and CSO Pam Vig in a fireside chat. The company is focused on developing therapies for rare liver diseases, with its lead candidate maralixibat under priority review by the FDA, aiming for a PDUFA date of September 29, 2021. Mirum is also pursuing gene therapy options for PFIC2 and PFIC3. For more details, visit the company’s website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
conferences
Rhea-AI Summary

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced new findings at the EASL International Liver Congress™ on its rare liver disease treatments. The analysis of maralixibat, used for Alagille syndrome, indicated strong safety over five years in 86 patients. Additionally, data from a multinational survey revealed significant quality of life impacts from pruritus in intrahepatic cholestasis of pregnancy, with a median itch severity of 9 out of 10. This underscores the urgent need for effective therapies for these liver conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none

FAQ

What is the current stock price of Mirum Pharmaceuticals (MIRM)?

The current stock price of Mirum Pharmaceuticals (MIRM) is $47.57 as of February 28, 2025.

What is the market cap of Mirum Pharmaceuticals (MIRM)?

The market cap of Mirum Pharmaceuticals (MIRM) is approximately 2.3B.

What is the focus of Mirum Pharmaceuticals, Inc.?

Mirum Pharmaceuticals focuses on developing and commercializing therapies for debilitating liver diseases, particularly rare and orphan conditions.

What is Maralixibat used for?

Maralixibat is an investigational oral drug for treating Progressive Familial Intrahepatic Cholestasis (PFIC), Alagille Syndrome (ALGS), and Biliary Atresia.

Where is Mirum Pharmaceuticals headquartered?

Mirum Pharmaceuticals is headquartered in Foster City, California.

What is Livmarli?

Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor approved for treating cholestatic pruritus in patients with Alagille Syndrome (ALGS).

When was Mirum Pharmaceuticals founded?

Mirum Pharmaceuticals was founded in 2018.

What is Volixibat being developed for?

Volixibat is being developed to treat Intrahepatic Cholestasis of Pregnancy (ICP) and Primary Sclerosing Cholangitis (PSC).

What are the recent achievements of Mirum Pharmaceuticals?

Recent achievements include the approval of Livmarli for treating cholestatic pruritus in ALGS patients and ongoing phase 3 trials for Maralixibat.

How does Mirum Pharmaceuticals contribute to the biopharmaceutical industry?

Mirum Pharmaceuticals contributes by developing novel therapies for rare liver diseases and establishing strategic partnerships to advance research.

How can I get the latest updates on Mirum Pharmaceuticals?

You can stay informed about the latest updates and stock performance of Mirum Pharmaceuticals on platforms like StockTitan.

What products are in Mirum Pharmaceuticals' pipeline?

Products in the pipeline include Maralixibat for PFIC and ALGS and Volixibat for ICP and PSC.
Mirum Pharmaceuticals

Nasdaq:MIRM

MIRM Rankings

MIRM Stock Data

2.30B
39.92M
2.24%
115.72%
13.85%
Biotechnology
Pharmaceutical Preparations
Link
United States
FOSTER CITY